All News

The association between current human papillomavirus vaccination trends and incidence of oropharynx cancer will be modest over the next 25 years.

As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.

Patients with muscle-invasive bladder cancer treated with gemcitabine and split-dose cisplatin plus pembrolizumab experienced improved pathological downstaging.

A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated cholangiocarcinoma who received ivosidenib vs placebo.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.

Refractory gastrointestinal stromal tumors can potentially be treated by using a KIT inhibitor combination of PLX9486 and sunitinib.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.

A recent trial found that patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer with prior disease control on standard EGFR inhibitors demonstrated efficacy and tolerability of mobocertinib.

Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.

Several factors among cancer survivors, such as rural residence, low income, and low education were found to be independently associated with a higher risk of developing new-onset cardiovascular disease.

The FDA has expanded the label for cetuximab/encorafenib for the treatment of patients with previously treated BRAF V600E–positive metastatic colorectal cancer.

A subset of patients with metastatic uveal melanoma achieved promising responses after treatment with entinostat and pembrolizumab.

Combination everolimus/letrozole yielded a higher progression-free survival over letrozole alone in a population of patients with hormone receptor (HR)–positive, ERBB2-negative advanced breast cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Although safety, efficacy, and symptom burden were not statistically different between patients with pulmonary oligometastases treated with single- or multi-fraction stereotactic ablative body radiotherapy, delivery appeared more efficient in the single-fractionation arm.

Patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib appear to benefit from treatment with pembrolizumab and best supportive care.

CancerNetwork speaks with Josh Ludwig on its latest podcast to discuss ScaleReady’s plans to make cell and gene therapy more practical and viable moving forward.

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

By not including race as part of the Chronic Kidney Disease-Epidemiology Collaboration equation, Black patients with cancer were more likely to not receive treatment for their disease.

Patients with mantle cell lymphoma who experience early relapse after being treated with either intensive or non-intensive frontline therapy are more likely to experience interior survival.

Patients with ROS1-positive non–small cell lung cancer may derive benefit from being treated with ROS1/NTRK inhibitor taletrectinib.

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

Final read-out of progression-free survival data from the ALTA-1L trial indicates significant benefit of brigatinib versus crizotinib for patients with ALK-positive non–small cell lung cancer who have not previously received an ALK inhibitor.

Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.

Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the decision to start the phase 2 MASTER trial for multiple myeloma.

Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide

Patients with early-stage non–small cell lung cancer experienced a survival benefit with adjuvant atezolizumab vs best supportive care.